Last Updated: November 4, 2026

Patent: 10,493,152

✉ Email this page to a colleague

Summary for Patent: 10,493,152

Title:	Adalimumab formulations
Abstract:	The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
Inventor(s):	Rinaldi; Gianluca (Monterotondo, RO), Fratarcangeli; Silvia (Ceprano, IT), Del Rio; Alessandra (Rome, IT)
Assignee:	Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:	15/313,480
Patent Claims:	see list of patent claims

Details for Patent 10,493,152

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	⤷ Start Trial	2035-05-15
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	⤷ Start Trial	2035-05-15
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	⤷ Start Trial	2035-05-15
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	⤷ Start Trial	2035-05-15
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	⤷ Start Trial	2035-05-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,493,152

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015263246	⤷ Start Trial
Australia	2018222887	⤷ Start Trial
Australia	2020201090	⤷ Start Trial
Australia	2022203863	⤷ Start Trial
Canada	2947487	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.